Verve Therapeutics, Inc.
VERV
$5.76
-$0.02-0.35%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 174.98% | 219.91% | 279.70% | 379.79% | 505.77% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 174.98% | 219.91% | 279.70% | 379.79% | 505.77% |
| Cost of Revenue | 19.47% | -82.73% | -85.55% | -86.65% | -85.30% |
| Gross Profit | 228.72% | 96.49% | 97.85% | 97.09% | 94.25% |
| SG&A Expenses | 13.44% | 11.68% | 12.08% | 20.86% | 33.05% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 11.12% | 11.77% | 13.45% | 21.70% | 40.12% |
| Operating Income | -2.48% | -4.45% | -6.50% | -15.46% | -34.67% |
| Income Before Tax | 0.72% | -2.19% | -0.20% | -9.66% | -26.99% |
| Income Tax Expenses | 26.91% | 4.05% | 18.34% | 618.87% | 418.87% |
| Earnings from Continuing Operations | 0.68% | -2.19% | -0.22% | -9.84% | -27.12% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 0.68% | -2.19% | -0.22% | -9.84% | -27.12% |
| EBIT | -2.48% | -4.45% | -6.50% | -15.46% | -34.67% |
| EBITDA | -1.95% | -3.75% | -5.56% | -14.39% | -33.64% |
| EPS Basic | 25.06% | 20.64% | 18.15% | 8.45% | -7.18% |
| Normalized Basic EPS | 25.09% | 20.63% | 18.16% | 8.60% | -7.06% |
| EPS Diluted | 25.06% | 20.64% | 18.15% | 8.45% | -7.18% |
| Normalized Diluted EPS | 25.09% | 20.63% | 18.16% | 8.60% | -7.06% |
| Average Basic Shares Outstanding | 32.05% | 29.48% | 23.86% | 21.31% | 18.85% |
| Average Diluted Shares Outstanding | 32.05% | 29.48% | 23.86% | 21.31% | 18.85% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |